-
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct 2021 12:47 GMT
… FDA's rolling review process supporting the new drug … advanced gastrointestinal stromal tumor who have received prior treatment with … therapy being developed for the treatment of non … Solution To Treat Interocular Pressure
Aerie Pharmaceuticals, Inc. …
-
Deciphera Pharma Reports Approval Of QINLOCK In Switzerland - Quick Facts
12 Oct 2021 11:20 GMT
Deciphera Pharmaceuticals, Inc. (DCPH) announced the Swiss … QINLOCK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have … received prior treatment with three or …
-
CHMP Adopts Positive Opinion For Deciphera's Qinlock To Treat Gastrointestinal Stromal Tumor
17 Sep 2021 14:37 GMT
Deciphera Pharmaceuticals Inc. (DCPH) said that the … ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) … who have received prior treatment with three …
-
Theseus Pharmaceuticals Announces Pricing of Initial Public Offering
07 Oct 2021 03:29 GMT
… state or jurisdiction. About Theseus Pharmaceuticals, Inc.
Theseus is a … therapies that address all major drug resistance mutations. Theseus' … the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed …
-
Middle East & Africa Active Pharmaceutical Ingredient Market to show Impressive Growth During the Forecast Period
02 Sep 2021 12:10 GMT
… , cure, mitigation, treatment, or prevention of … food and drug administration, FDA.
Browse over … and development of the drugs and other pharmaceutical products … Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor, Gastric Neuroendocrine Tumors), …
-
Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
02 Sep 2021 11:00 GMT
… Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing … in kinase biology to develop a broad portfolio of … FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor …
-
Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
02 Sep 2021 11:00 GMT
… Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing … in kinase biology to develop a broad portfolio of … FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor …
-
Two studies on gastrointestinal stroma tumors describe advances that may lead to new treatments
25 Aug 2021 04:51 GMT
… major impediments to treating GIST is the … treatment.
Establishment of patient-derived succinate dehydrogenase-deficient gastrointestinal stromal tumor … standard of care medications, such as tyrosine … molecular understanding and drug development.
In their paper …
-
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
31 Mar 2021 08:57 GMT
… Pharmaceuticals (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing … profile in treating advanced GIST … FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumors … for any drugs or …
-
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results
03 Aug 2021 20:58 GMT
… treating the first patient in our Phase 1 trial … Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing … FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor …
About
© 1995-2021